drugset / Trial / NCT00060489

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

NCT00060489

Phase 3 Completed AstraZeneca
Treatment

Summary

The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.

Timeline

Start
2002-09
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 300 mg
Subject Quetiapine Small molecule 600 mg

Indications